[A novel molecular target therapeutics for refractory prostate cancer].
Uemura
Hiroji
H
Department of Urology, Yokohama City University School of Medicine.
Ikeda
Naoya
N
Nakaigawa
Noboru
N
Ouchi
Hideki
H
Ishiguro
Hitoshi
H
Kubota
Yoshinobu
Y
D000077556:Alitretinoin; D000728:Androgens; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001562:Benzimidazoles / Q000627:therapeutic use; D001713:Biphenyl Compounds; D002762:Cholecalciferol / Q000627:therapeutic use; D004268:DNA-Binding Proteins; D015195:Drug Design; D019833:Genistein / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000209:etiology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000209:etiology; D044140:Receptor, Angiotensin, Type 1; D011945:Receptors, Angiotensin / Q000502:physiology; D019098:Telomerase / Q000037:antagonists & inhibitors; D013777:Tetrazoles / Q000627:therapeutic use; D014212:Tretinoin / Q000627:therapeutic use
D000728:Androgens; D057911:Angiotensin Receptor Antagonists; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D004268:DNA-Binding Proteins; D044140:Receptor, Angiotensin, Type 1; D011945:Receptors, Angiotensin; D013777:Tetrazoles; D002762:Cholecalciferol; D000077556:Alitretinoin; D014212:Tretinoin; D019833:Genistein; D019098:Telomerase; C081643:candesartan